Second-line therapy for refractory renal-cell carcinoma.
about
Multidisciplinary management of clear-cell renal cell carcinoma in Africa and the Middle East: current practice and recommendations for improvementOptimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence.Experience with sorafenib in the treatment of advanced renal cell carcinoma.PI3K/AKT signaling pathway and cancer: an updated review.Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives.Everolimus as second-line therapy for metastatic renal cell carcinoma: a 'real-life' study.We need both randomized trials and real-world data: the example of everolimus as second-line therapy for mRCC.The Role of Everolimus in Renal Cell Carcinoma.
P2860
Q26801279-2970B20C-4E81-4362-A5A3-E433ECC2E07FQ34666150-423C53FA-17BC-4BF9-9A69-53F77A35E24BQ36379345-7F557CCC-67B4-4A50-B885-680B388EF8EBQ38217651-EB30CC5B-FDFD-46F5-96F2-367C8A23AE7CQ38527936-89872B5D-FF47-446A-BF2C-3C4A8D0FC293Q39150764-D7A6EAA2-5FFA-44E3-8107-2F0A0EE6A2FAQ51217838-BC9DD17F-12B1-42BF-8378-463AC91FF52FQ52979097-9414A405-5F4E-4648-90C1-5F16E7DC65A4
P2860
Second-line therapy for refractory renal-cell carcinoma.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Second-line therapy for refractory renal-cell carcinoma.
@en
Second-line therapy for refractory renal-cell carcinoma.
@nl
type
label
Second-line therapy for refractory renal-cell carcinoma.
@en
Second-line therapy for refractory renal-cell carcinoma.
@nl
prefLabel
Second-line therapy for refractory renal-cell carcinoma.
@en
Second-line therapy for refractory renal-cell carcinoma.
@nl
P2093
P1476
Second-line therapy for refractory renal-cell carcinoma
@en
P2093
Davide Pastorelli
Fable Zustovich
Ornella Nicoletto
P304
P356
10.1016/J.CRITREVONC.2011.08.008
P577
2011-09-22T00:00:00Z